Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evolocumab in STEMI
Sponsor: Sejong General Hospital
Summary
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.
Official title: The Effect of Evolocumab on Infarct Size in Patients With ST-segment Elevation Myocardial Infarction; Prospective, Randomized, Open Label, Controlled Trial
Key Details
Gender
All
Age Range
30 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
166
Start Date
2020-12-05
Completion Date
2025-12-31
Last Updated
2025-06-19
Healthy Volunteers
No
Conditions
Interventions
Repatha®
Repatha® 140mg x 3 pens subcutaneous injection
Locations (1)
Sejong General Hospital
Bucheon-si, South Korea